Abstract

BackgroundLactic acid produced by tumors has been shown to overcome immune surveillance, by suppressing the activation and function of T cells in the tumor microenvironment. The strategies employed to impair tumor cell glycolysis could improve immunosurveillance and tumor growth regulation. Dichloroacetate (DCA) limits the tumor-derived lactic acid by altering the cancer cell metabolism.In this study, the effects of lactic acid on the activation and function of T cells, were analyzed by assessing T cell proliferation, cytokine production and the cellular redox state of T cells. We examined the redox system in T cells by analyzing the intracellular level of reactive oxygen species (ROS), superoxide and glutathione and gene expression of some proteins that have a role in the redox system. Then we co-cultured DCA-treated tumor cells with T cells to examine the effect of reduced tumor-derived lactic acid on proliferative response, cytokine secretion and viability of T cells.ResultWe found that lactic acid could dampen T cell function through suppression of T cell proliferation and cytokine production as well as restrain the redox system of T cells by decreasing the production of oxidant and antioxidant molecules. DCA decreased the concentration of tumor lactic acid by manipulating glucose metabolism in tumor cells. This led to increases in T cell proliferation and cytokine production and also rescued the T cells from apoptosis.ConclusionTaken together, our results suggest accumulation of lactic acid in the tumor microenvironment restricts T cell responses and could prevent the success of T cell therapy. DCA supports anti-tumor responses of T cells by metabolic reprogramming of tumor cells.

Highlights

  • Cancer immunotherapy through adoptive cellular therapy (ACT) and its derivative, chimeric antigen receptor (CAR) T cells, has shown clinical effectiveness for hematological malignancies and immunogenic tumors such as melanoma but the efficacy of ACT for solid tumorsLactic acid accumulation in tumors is a by-product of hypoxia which occurs when tumors switch to an anaerobic metabolism

  • Proliferation and cytokine secretion was suppressed by lactic acid We investigated the effect of lactic acid on various properties of T cells that have a role in T cell activation

  • The lactic acid concentration was set to 20 mM, which matches the lactic acid concentration experienced by T cells in previously published studies in human and murine tumors [20,21,22]

Read more

Summary

Introduction

Cancer immunotherapy through adoptive cellular therapy (ACT) and its derivative, chimeric antigen receptor (CAR) T cells, has shown clinical effectiveness for hematological malignancies and immunogenic tumors such as melanoma but the efficacy of ACT for solid tumorsLactic acid accumulation in tumors is a by-product of hypoxia which occurs when tumors switch to an anaerobic metabolism. Lactic acid produced by highly glycolytic tumors has been shown to overcome immune surveillance by suppressing activation of NK and infiltrating T cells and inhibiting the proliferation and cytokine production of T lymphocytes [8, 9]. PDK inhibition with the drug dichloroacetate (DCA) changes the cancer cell metabolism from glycolysis towards mitochondrial glucose oxidation and as a result reduces lactic acid levels [18]. Lactic acid produced by tumors has been shown to overcome immune surveillance, by suppressing the activation and function of T cells in the tumor microenvironment. The effects of lactic acid on the activation and function of T cells, were analyzed by assessing T cell prolif‐ eration, cytokine production and the cellular redox state of T cells. We co-cultured DCA-treated tumor cells with T cells to examine the effect of reduced tumor-derived lactic acid on proliferative response, cytokine secretion and viability of T cells

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call